SCHEMBL9864828

SCHEMBL9864828

O=C1CCCN1Nc1cccc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.45
TP53 P04637 1/20 0.45
GLA P06280 1/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALOX5 P09917 1/20 0.42
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CA12 O43570 1/20 0.40
MMP2 P08253 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PPIA P62937 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1829012 0.80 HTT (0.49) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL19858912 0.78 NPC1 (0.51) NPC1RAB9AALDH1A1TP53ALOX5
SCHEMBL1625851 0.75 LMNA (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL19955101 0.74 NAAA (0.41) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL5547476 0.73 ALDH1A1 (0.54) NPC1RAB9AKDM4EALDH1A1TP53
SCHEMBL5550694 0.71 ALDH1A1 (0.53) NPC1RAB9AKDM4EALDH1A1TP53
SCHEMBL9377097 0.70 APOBEC3A (0.38) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL8416230 0.70 FFAR1 (0.49) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL7496243 0.69 POLB (0.51) NPC1RAB9A
SCHEMBL19858926 0.67 SMN1; SMN2 (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10112929-B2 Lactams as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-10-30 US disclosed
US-20180044326-A1 LACTAMS AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMAPANY (US) 2018-02-15 US disclosed
US-5077160-A PHOTOCONDUCTIVE IMAGING MEMBERS WITH FLUORINATED SQUARAINE COMPOSITIONS XEROX CORPORATION (US) 1991-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044326-A1 LACTAMS AS INHIBITORS OF ROCK MYLK, ROCK1, RHOA NPC1 4383/4885RAB9A 433/4885KDM4E 1408/4885
US-10112929-B2 Lactams as inhibitors of rock MYLK, ROCK1, RHOA NPC1 4391/4885RAB9A 428/4885KDM4E 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.